Can a simple dye test spot kidney trouble in the ICU?

NCT ID NCT02050269

First seen Jan 04, 2026 · Last updated Jun 19, 2026 · Updated 26 times

Summary

This study tested whether a dye called iohexol can accurately measure kidney function in 100 ICU patients with unstable blood pressure. The goal was to see if this method could help detect acute kidney injury earlier than current tests. Researchers tracked how quickly the dye cleared from the blood and compared it to other kidney injury markers.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE CIRCULATORY FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Hospital La SOURCE

    Orléans, 45000, France

  • Service de Réanimation Polyvalente, CHRU de Tours

    Tours, 37044, France

  • University Hospital Strasbourg

    Strasbourg, 67000, France

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Iohexol (a contrast dye)

What this could lead to

If successful, this could provide a more accurate way to measure kidney function in critically ill patients, helping doctors detect kidney injury earlier.

What could go wrong

This is a small feasibility study, not a treatment trial. The method may not be practical or accurate enough for routine ICU use, and iohexol carries a small risk of allergic reactions.

Conditions

The condition(s) this trial relates to.

Shock

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.